Literature DB >> 16532495

Impact of overlapping drug-eluting stents in patients undergoing percutaneous coronary intervention.

William W Chu1, Pramod K Kuchulakanti, Rebecca Torguson, Betty Wang, Leonardo C Clavijo, William O Suddath, Augusto D Pichard, Lowell F Satler, Kenneth M Kent, Ron Waksman.   

Abstract

BACKGROUND: Sirolimus-eluting stent (SES) implantation for the treatment of single coronary lesions is proven to be effective and durable. However, the safety and efficacy of overlapping SES for the treatment of long lesions have not been well established.
OBJECTIVES: We conducted a retrospective analysis to compare the clinical outcomes of overlapping versus nonoverlapping SES.
METHODS: Fifty-five patients who received overlapping SES were compared with 39 patients who received nonoverlapping SES.
RESULTS: The baseline clinical and angiographic characteristics were balanced between the two study groups. The in-hospital complications were similar between groups, except that non-Q-wave myocardial infarction was significantly higher in the Overlapping SES group when compared with the Nonoverlapping SES group (23.6% vs. 7.7%, P = 0.04). This higher rate of myonecrosis is due to periprocedural side branch compromises, including side branch narrowing, occlusion, and flow reduction. At 30 days and 6 months follow-up, all clinical outcomes were similar between the study groups. In addition, the event-free survival rate was similar between groups (P = 0.87).
CONCLUSIONS: The implantation of overlapping SES for the treatment of long, native coronary lesions is feasible and effective but is associated with an increased rate of periprocedural myonecrosis. This phenomenon is caused primarily by side branch compromises, but does not have any adverse impact on late clinical events.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16532495     DOI: 10.1002/ccd.20665

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  4 in total

Review 1.  How to manage patients with need for antiplatelet therapy in the setting of (un-)planned surgery.

Authors:  Helge Möllmann; Holger M Nef; Christian W Hamm; Albrecht Elsässer
Journal:  Clin Res Cardiol       Date:  2008-10-13       Impact factor: 5.460

2.  Two-year clinical outcomes of patients with long segments drug-eluting stents: comparison of sirolimus-eluting stent with paclitaxel-eluting stent.

Authors:  Ung Kim; Sang-Hee Lee; Geu-Ru Hong; Jong-Seon Park; Dong-Gu Shin; Young-Jo Kim; Jae-Sik Jang; Tae-Hyun Yang; Dae-Kyeong Kim; Dong-Soo Kim; Dong-Kie Kim; Sang-Hoon Seol; Doo-Il Kim; Yoon-Kyung Cho; Hyung-Seop Kim; Chang-Wook Nam; Seung-Ho Hur; Kwon-Bae Kim
Journal:  J Korean Med Sci       Date:  2011-10-01       Impact factor: 2.153

3.  Outcomes of stenting with overlapping drug-eluting stents versus overlapping drug-eluting and bare-metal stents for the treatment of diffuse coronary lesions.

Authors:  S E Kassaian; M Salarifar; M Raissi Dehkordi; M Alidoosti; E Nematipour; H R Poorhosseini; A M Hajizeinali; D Kazemisaleh; A Sharafi; M Mahmoodian; N Paydari; A V Farahani
Journal:  Cardiovasc J Afr       Date:  2010 Nov-Dec       Impact factor: 1.167

4.  The angiography-guided spot versus entire stenting in patients with long coronary lesions trial: Study design and rationale for a randomized controlled trial protocol.

Authors:  Ju Yeol Baek; Seung Woon Rha; Byoung Geol Choi; Cheol Ung Choi; Kyoung-Ha Park; Byung Hee Hwang; Seung-Jin Lee; Young Keun Ahn; Jae Woong Choi; In-Ho Chae; Won Ho Choi; Young-Hyo Lim; Ji Hoon Ahn; Woong Gil Choi
Journal:  Contemp Clin Trials Commun       Date:  2020-01-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.